A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder | NCT00189800 | Trialant
CompletedInterventionalPhase 3Updated Nov 17, 2011
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
ClinicalTrials.gov ID
NCT00189800
Lead Sponsor
Astellas Pharma IncINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Nov 17, 2011Estimated
Brief Summary
The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.
Overactive Bladder
Solifenacin succinate
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Symptoms of overactive bladder
Must be able to complete the micturition diary
Exclusion Criteria:
Pregnant or lactating
Clinically significant outflow obstruction
Significant post void residual urine
Significant stress incontinence
Urinary tract infection
Chronic inflammation
Bladder stones
Previous pelvic radiation therapy
Previous or current malignant disease of the pelvic organs